{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:41:00Z","timestamp":1790624460243,"version":"4.1.0"},"reference-count":14,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,4,28]]},"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>A man in his 80s was undergoing immunotherapy with pembrolizumab, an anti-PD-1 monoclonal antibody, following his diagnosis of adenocarcinoma of primary lung origin. 24 weeks into treatment, the patient reported experiencing loose stools associated with malaise and poor appetite but no further symptoms. This progressed in frequency and a clinical diagnosis of grade 2 immune checkpoint inhibitor colitis was made. Management with oral prednisolone was commenced but symptoms persisted. Common enteric infections had been ruled out, as were coeliac disease and hyperthyroidism. Flexible sigmoidoscopy and colonoscopy results were not in keeping with colitis, having revealed normal looking mucosa. Following this, a faecal elastase level was found to be low. A diagnosis of pembrolizumab-induced pancreatic exocrine insufficiency was made, and stool frequency and consistency swiftly improved following the use of pancreatic enzyme replacement therapy.<\/jats:p>","DOI":"10.1136\/bcr-2023-259057","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T12:55:58Z","timestamp":1715172958000},"page":"e259057","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Immune checkpoint inhibitor associated diarrhoea"],"prefix":"10.1136","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5106-5623","authenticated-orcid":false,"given":"Amin","family":"Al-Hussainy","sequence":"first","affiliation":[{"name":"Wexham Park Hospital, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joss","family":"Adams","sequence":"additional","affiliation":[{"name":"Royal Berkshire Hospital, Reading, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Simmons","sequence":"additional","affiliation":[{"name":"Royal Berkshire Hospital, Reading, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Royal Berkshire Hospital, Reading, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,5,8]]},"reference":[{"key":"2025082722374990000_17.5.e259057.1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/apjon.apjon_4_17","article-title":"Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer","volume":"4","author":"Dine","year":"2017","journal-title":"Asia Pac J Oncol Nurs"},{"key":"2025082722374990000_17.5.e259057.2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025082722374990000_17.5.e259057.3","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000958","article-title":"Immune checkpoint inhibitor-associated celiac disease","volume":"8","author":"Badran","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025082722374990000_17.5.e259057.4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00251-017-1015-5","article-title":"PD-1 and cancer: molecular mechanisms and polymorphisms","volume":"70","author":"Salmaninejad","year":"2018","journal-title":"Immunogenetics"},{"key":"2025082722374990000_17.5.e259057.5","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00386","article-title":"Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion","volume":"8","author":"Dong","year":"2018","journal-title":"Front Oncol"},{"key":"2025082722374990000_17.5.e259057.6","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2025082722374990000_17.5.e259057.7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225"},{"key":"2025082722374990000_17.5.e259057.8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2217\/imt-2017-0126","article-title":"Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy","volume":"10","author":"Prasanna","year":"2018","journal-title":"Immunotherapy"},{"key":"2025082722374990000_17.5.e259057.9","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/annonc\/mdw626","article-title":"Atrophic exocrine pancreatic insufficiency associated with anti-PD1 therapy","volume":"28","author":"Hoadley","year":"2017","journal-title":"Ann Oncol"},{"key":"2025082722374990000_17.5.e259057.10","article-title":"Pembrolizumab-induced pancreatic exocrine insufficiency complicated by severe hepatic steatosis","volume":"14","author":"Hong","year":"2022","journal-title":"Cureus"},{"key":"2025082722374990000_17.5.e259057.11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/CJI.0000000000000472","article-title":"Immune checkpoint inhibitor-related pancreatitis: a case series, review of the literature and an expert opinion","volume":"46","author":"Kramer","year":"2023","journal-title":"J Immunother"},{"key":"2025082722374990000_17.5.e259057.12","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315909"},{"key":"2025082722374990000_17.5.e259057.13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41416-020-0882-y","article-title":"Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way","volume":"123","author":"Cheung","year":"2020","journal-title":"Br J Cancer"},{"key":"2025082722374990000_17.5.e259057.14","doi-asserted-by":"publisher","DOI":"10.4997\/JRCPE.2018.306"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-259057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:38:00Z","timestamp":1756359480000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-259057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":14,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,8]]},"published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1136\/bcr-2023-259057"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-259057","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}